ArticleTranslational cancer research2025
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- The predictive value of prognostic immune and nutritional index in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy: a retrospective propensity score matching study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, there is a surge in clinical trials investigating neoadjuvant immunotherapy (NAI) and its combination with other treatments for resectable esophageal squamous cell carcinoma (ESCC). However, systematic evaluations of these studies are relatively scarce. This study aims to explore the latest evidence on the survival benefits of NAI combined with chemotherapy (NAIC) for patients with resectable ESCC. Methods: Relevant literature was searched in PubMed, Embase, The Cochrane Library, and Web of Science databases up to July 16, 2024. Studies meeting the research criteria were selected. Endpoints included pathological complete response (pCR), major pathological response (MPR), surgery rate (SR), R0 resection rate, pathological downstaging rate (PDR), programmed death-ligand 1 (PD-L1) expression (≤1%) rate, partial response (PR), objective response rate (ORR), overall survival (OS), event-free survival (EFS), incidence of any-grade treatment-related adverse events (TRAEs), and incidence of grade 3-5 TRAEs. Results: A total of 44 studies involving 2,333 patients were included. The meta-analysis showed that the pooled pCR rate and MPR rate were 28% [95% confidence interval (CI): 25-31%] and 52% (95% CI: 46-58%), respectively, PR rate was 60% (95% CI: 51-68%), and ORR rate was 76% (95% CI: 69-83%). The 1-, 2-, and 3-year OS rates were 92% (95% CI: 89-96%), 86% (95% CI: 82-91%), and 81% (95% CI: 72-90%), respectively. The 1- and 2-year EFS rates were 88% (95% CI: 82-94%) and 83% (95% CI: 77-90%), respectively. The incidence of any-grade TRAEs was 69% (95% CI: 56-81%), and the incidence of grade 3-5 TRAEs was 19% (95% CI: 14-23%). Subgroup analysis showed that pembrolizumab and tislelizumab had higher pCR and MPR rates, but tislelizumab was associated with a higher incidence of grade 3-5 TRAEs. Four cycles of neoadjuvant therapy were more effective than 2-3 cycles. Conclusions: This study demonstrates that NAIC is an effective and safe neoadjuvant treatment modality for patients with resectable ESCC, providing significant therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.